Anacor Pharmaceuticals announces commencement of AN5568 trials

RELATED QUOTES

SymbolPriceChange
ANAC5.66-0.43

Anacor Pharmaceuticals announced that its collaboration partner, the Drugs for Neglected Diseases initiative, has commenced Phase 1 clinical studies of SCYX-7158, also referred to as AN5568, the first new oral drug candidate discovered specifically to combat human African trypanosomiasis, also known as sleeping sickness. AN5568 was discovered utilizing Anacor’s boron-based chemistry and is Anacor’s sixth compound to enter human clinical development since the company was started ten years ago.

  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    Do you trust the IRS in light of its recent scandals?

    Loading...
    Poll Choice Options